Проблема диагностики шизофрении у больных, потребляющих психоактивные вещества

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Фастовцов Г.А., Осколкова С.Н. Проблема диагностики шизофрении у больных, потребляющих психоактивные вещества // Российский психиатрический журнал. 2018. №5. С. 51-63.

Аннотация

В научном обзоре с целью анализа сочетаний симптоматики шизофрении и проявлений потребления психоактивных веществ рассмотрен аспект дифференциации эндогенной и экзогенной психопатологии. Обзор основан на анализе 35 отечественных и 25 зарубежных научных работ, посвящённых вопросам дифференциальной диагностики разных этапов и проявлений шизофрении и последствий употребления наркотиков, особенно интоксикационных психозов. Объектом внимания являлись как давно известные наркотики, так и последнего поколения – синтетические. Проведённый обзор позволил сделать вывод о недостаточной изученности указанных проблем, несмотря на актуальность для общей и судебной психиатрии и наркологии, предупреждения правонарушений, для общества в целом. Дальнейшее изучение интоксикационных психозов и расстройств, обусловленных шизофренией в сочетании с употреблением наркотиков, могут открыть новые страницы патогенеза психопатологии шизофренического спектра и новые возможности профилактики обращения к наркотикам.

Ключевые слова Психиатрия; Медицина; Психология

Литература

1. Sivolap YuP, Yanushkevich MV, Savchenkov VA. Dvoynoy diagnoz: shizofreniya i zloupotreblenie psikhoaktivnymi veshchestvami. Nevrologicheskiy vestnik. 2017;XLIX(2):57–60. Russian. 2. Mueser RT, Ginderich S. Treatment of co-occuring psychotic and substance use disorders. Soc Work Public Health. 2013;28(2–4):424–39. DOI: 10.1080/19371918.2013.774676 3. Anderson HL, Semple DM, Blayney C, et al. Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. Psychol Med. 2017;3:1–8. DOI: 10.1017/S0033291717001118 4. Dobrovol'skaya AE, Sofronov AG, Pashkovskiy VE. Nekotorye sotsial'no-demograficheskie i kliniko-dinamicheskie pokazateli bol'nykh shizofreniey, otyagoshchennoy zloupotrebleniem PAV. Narkologiya. 2012;2:50–3. Russian. 5. Dervaux A, Laqueille X, Bourdel MC, et al. [Cannabis and schizophrenia: demographic and clinical correlates]. Encephale. 2003;29(1):11–7. DOI: enc-2-2003-29-1-0013-7006-101019-art2 6. Walter M. Co-occuring addictive and psychiatric disorders. Berlin-Heidelberg: Springer; 2015. p. 137–48. 7. Dixon L, Haas G, et al. Acute Effects of Drug Abuse in Schizophrenic Patients: Clinical Observations and Patients' Self-reports. Schizophr Bull. 1990;16(1):69–79. DOI: 10.1093/schbul/16.1.69 8. Oskolkova SN. Differentcialnaya diagnostica schizophrenii I residualno-organicheskogo porazhеniya golovnogo mozga pri psichipathopodobnich sostoyaniyach (voprisy cliniki i optimizatsii diagnosticheskogo prоcesssa): [PhD thesis]. [Moscow (Russia)]: Gosud naucniy center social. i sudebnoi psichiatrii im. VP Serbskogo (Federal scientific center of social and forensic psychiatry named by VP Serbski); 1992. 45 p. Russian. 9. Shumskiy NG. Diagnosticheskie oshibki v sudebno-psychiatricheskoy practice. Moscow; 1997. 400 p. Russian. 10. Snezhnevskiy AV. Pozdnie simptomaticheskie psikhozy. Trudy instituta im. PB Gannushkina. 1940;5:156–275. Russian. 11. Mendelevich VD. Psihoticheskie rasstrojstva v rezul'tate upotreblenija narkotikov: sovremennoe sostojanie problem [Psychotic disorders due to drug use: the current state of the problem] // Narkologija [Narcology]. 2014;7:93–100. Russian. 12. Makushkin EV. Agressivnoe kriminalnoe povedenie u detey i podrostkov s narushennyim razvitiem [Aggressive criminal behavior in children and adolescents with disturbed development]. Moscow; 2009. 240 p. Russian. 13. Bulygina IE. Klinicheskie proyavleniya intoksikatsii novym psikhoaktivnym veshchestvom MDMB(N)-Bz-F. Materialy Vserossiyskoy nauchno-prakticheskoy konferentsii «Sovershenstvovanie pravovykh osnov narkologicheskoy pomoshi». Moscow; 2014. p. 45–52. Russian. 14. Van der Veer N, Friday J. Persistent psychosis following the use of Spice. Sch Research. 2011;130(1–3):285–6. DOI: 10.1016/j.schres.2011.04.022 15. Miller VH, Sperling WK, et al. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Sch Res. 2010;18(1–3):309–10. DOI: 10.1016/j.schres.2009.12.001 16. Soldatkin VA, Mendelevich VD, Sivolap YuP, et al. Rezidual'noe psikhoticheskoe rasstroystvo vsledstvie upotrebleniya psikhostimulyatorov il shizofreniya? (Klinicheskiy razbor). Nevrologicheskiy vestnik. 2017;XLIX(2):78–90. Russian. 17. Lyubov EB. [Substance-dependent patients as a risk group for suicidal behavior]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2017;(3):19–26. Russian. 18. Bokhan AN, Voevodin IV. Autodestruktivnost' v formirovanii addiktivnykh i nevroticheskikh rasstroystv. [Self-destruction in the formation of addictive and neurotic disorders: suicidal and risk-taking behaviour]. Obozrenie psikhiatrii i meditsinskoy psikhologii im. VM Bekhtereva. 2016;1:59–65. Russian. 19. Megrabyan AA, Oganesyan VO, Melik-Pashayan MA. Rol' gashishnoy intoksikatsii v klinicheskoy kartine shizofrenii. Alkogolizm i drugie infektsionnye zabolevaniya TsNS i psikhicheskoy sfery. Tashkent; 1972. p. 99–102. Russian. 20. Gilenko MV. Kliniko-sotsial'nye korrelyatsii protivopravnoy aktivnosti bol'nykh shizofreniey, zloupotreblyayushchikh narkotikami // Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2004;(5):13–6. Russian. 21. Goswami S, Mattoo SK, Basu D, et al. Substance-abusing schizophrenics: do they self-medicate? Am J Addict. 2004;13(2):139–50. DOI: 10.1080/10550490490435795 22. Ovsyannikov MV, Chirko VV, Morozov GV, et al. Addiktivnye rasstroystva u bol'nykh shizofreniey. Moscow; 2008. 256 p. Russian. 23. Hermle L, Szlak-Rubin R, Taschner KL, et al. Substance use associated disorders: frequency in patients with schizophrenia and affective psychoses. Der Nervenarzt. 2013;84(3):315–25. DOI: 10.1007/s00115-011-3459-4 24. Sund R, Putkonen H, et al. Substance-induced psychoses converting into schizophrenia: a register – based study of 18,478 Finnish cases. J Clin Psychiatry. 2013;11:449–68. DOI: 10.4088/JCP.12m07822 25. Drugs of Abuse, A DEA resourse guide. Drug Enforcement Administration. Department of Justice; 2017. p. 1–94. 26. Коshеlevа ТC. Stoikie psikhitcheskie rasstroistva vsledstvie zloupotreblenia psichostimulatorami s amphetaminopodobnim deistviem (кlinicheskiy i sudebno-psichiatricheskiy aspect) [PhD thesis]. [Moscow (Russia)]: Gosud. Nauchniy center social. i sudebnoi psichiatrii im. VP Serbskogo (Federal scientific center of social and forensic psychiatry named by VP Serbski); 2005. 31 p. Russian. 27. Sharova EN, Zlokazova MV. Fenomenologicheskie osobennosti psikhicheskikh rasstroystv ot sovremennykh «dizaynerskikh narkotikov» [Phenomenological peculiarities of psychic disorders caused by modern «designer» drugs] // Prakticheskaya meditsina [Practical medicine]. 2017;2(1):23–5. Russian. 28. Chernyshova OA., Odinets AD. Nekotorye osobennosti intoksikatsionnykh psikhozov, vyzvannykh upotrebleniem «dizaynerskikh narkotikov». Sbornik statey XI mezhdunarodnoy nauchno-prakticheskoy konferentsii «Advances in sciences and technology». Moscow; 2017. p. 37–40. Russian. 29. Olivier B, van Oorschot R. 5-HT1B receptors and aggression: A review. Eur J Pharmacol. 2005;526(1–3):207–17. DOI: 10.1016/j.ejphar.2005.09.066 30. Thornton S, Gerona R, Tomaszewski C. Psychosis from a Bath Salt Product Containing Flephedrone and MDPV with Serum, Urine, and Product Quantification. J Medical Toxicology. 2012;8(3):310–3. DOI:10.1007/s13181-012-0232-4 31. Pozdnyakova ME. Narkotiki novoy volny kak faktor izmeneniya narkosituatsii v Rossii. Sotsiologicheskaya nauka i sotsial'naya praktika. 2013;(2):123–39. Russian. 32. Castanedo MS, Gorelic DA, Desrosiers NA, et al. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;114:12–41. DOI: 10.1016/j.drugalcdep.2014.08.005 33. Klembovskaya EV, Sat'yanova LS, Mustafina TB. Klinicheskie osobennosti i sudebno-psikhiatricheskaya otsenka psikhoticheskikh sostoyaniy, vyzvannykh upotrebleniem MDPV («Soli»). Voprosy narkologii. 2017;(8):119–20. Russian. 34. Vandysh-Bubko VV, Gilenko MV, Krivenkova NS. Sudebno-psikhiatricheskaya otsenka ostrogo psikhoticheskogo rasstroystva v svyazi s upotrebleniem sinteticheskikh stimulyatorov. Praktika SPE № 56. Ed. by Fastovtsov GA. Мoscow; 2018. p. 111–23. Russian. 35. Fastovtsov GA, Oskolkova SN. Ostroe psikhoticheskoe sostoyanie shizofrenoformnoy struktury s tyazhelymi kriminal'ny. IGA Fastovtsov (ed.). Praktika sudebno-psikhiatricheskoy ekspertizy. 2018;(56):86–96. Russian. 36. Igonin AL, Kekelidze ZI, Klimko TV. Klinicheskaya, pravovaya i ekspertnaya otsenka razlichnykh sostoyaniy, vyzyvaemykh upotrebleniem PAV (s uchetom poslednikh izmeneniy v rossiyskom zakonodatel'stve). 2015; 172 p. Russian. 37. Chukhlovina ML. Kognitivnye narusheniya u lits, zloupotreblyayushchikh psikhoaktivnymi veshchestvami [Cognitive impairments in psychoactive drug addicts]. Zhurnal nevrologii i psikhiatrii im SS Korsakova. 2015;115(6):83–5. DOI: 10.17116/jnevro20151156183-85. Russian. 38. Kekelidze ZI, Klimenko TV, Kozlov AA. Lechenie ostrogo psikhoza vsledstvie upotrebleniya sinteticheskikh kannabioidov. Sibirskiy vestnik psikhiatrii i narkologii. 2017;3(96):16–20. Russian. 39. Kozlov AA, Shakhova SM, Klimenko TV. Sovremennyy kompleksnyy podkhod k organizatsii meditsinskoy pomoshchi bol'nym s psikhoticheskimi rasstroystvami vsledstvie upotrebleniya sinteticheskikh kannabinoidov. Materialy VII Natsional'nogo Kongressa po sotsial'noy psikhiatrii i narkologii. Tyumen; 2018. p. 104–5. Russian. 40. Zdravoochranenie v Rossii. 2017: statisticheskiy sbornik. Moscow; 2018. 170 p. Russian. 41. Doklad Mezhdunarodnoy komissii po kontrolyu nad narkotikami OON [Report of the UN Commission on Narcotic Drugs]. Narkologiya. 2017;(12):3–8. Russian. 42. Asanov TR. Sostoyanie ostriy gashishnoy u litc s socheyannoy psychicheskoy pathologiey (klinicheskie varianti, differentcialnays diagnostica, sudebno-psychiatricheskaya otcenka) [PhD thesis]. [Moscow (Russia)]: Gosud. Nauchniy center social. i sudebnoi psichiatrii im. VP Serbskogo. Moscow; 1997. 20 p. Russian. 43. Subkhaberdina AS. Kriminal'naya aktivnost' lits s opioidnoy zavisimost'yu v strukture sochetannoy psikhicheskoy patologii [PhD thesis]. [Moscow (Russia)]: Gosud. Nauchniy center social. i sudebnoi psichiatrii im. VP Serbskogo (Federal scientific center of social and forensic psychiatry n.a. VP Serbski); 2004. 40 p. Russian. 44. Aleksandrovskiy YA. Predboleznennye sostoyaniya i pogranichnye psikhicheskie rasstroystva. Moscow; 2010. 272 p. Russian. 45. Meyer MR, Wilhelm J, Peters F, et al. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone. J Anal Bioanal Chem. 2010;397:1225–33. DOI: 10.1007/s00216-010-3636-5 46. Prokhorenko VV. Vyyavlenie i raskrytie prestupleniy, svyazannykh s rasprostraneniem sinteticheskikh narkotikov. Aktual'nye problemy bor'by s prestupleniyami i inymi pravonarusheniyami. 2013;11(1):61–3. Russian. 47. Klimenko TV. Osnovnye zakonomernosti razvitiya shizofrenii pri ee sochetanii s narkomaniey. Sochetannye psikhicheskie rasstroystva razlichnogo geneza v sudebno-psikhiatricheskoy praktike. Мoscow; 1991. p. 33–7. Russian. 48. Zisook S, Heaton R, Moranville J, et al. Past substance abuse and clinical course of schizophrenia. Am J Psychiatry. 1992;149:552–3. DOI: 10.1176/ajp.149.4.552 49. Allebeck Р, Adamsson С, Engstrom, et al. Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand. 1993;88:21–4. DOI: 10.1111/j.1600-0447.1993.tb03408.x 50. Вleuler E. Autisticheskoe myshlenir. Odessa; 1927. 81 p. Russian. 51. Kornilov AP. Osobennosti samoregulyatsii u bol'nykh shizofreniey. Psikhologicheskiyzhurnal. 1996;4:116–25. Russian. 52. Kępiński A. Schizofrenia. Warsaw; 1972. 294 p. Russian. 53. Safuanov FS. Psikhologiya kriminal'noy agressii. Мoscow; Smysl, 2003. 300 p. Russian. 54. Carra G, Johnson S, Bebbingto P, et al. The lifetime and past-year prevalеnce of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort. European Archives of Psychiatry and Clinical Neuroscirnce. 2012;56(1):44–50. DOI: 10.1007/s00406-012-0305-z 55. Litvintsev SV, Mishurskiy EE, Kargin AA. Nekotorye voprosy komorbidnosti shizofrenii i addiktivnykh rasstroystv. Materialy XIV s'ezda psikhiatrov Rossii. Moscow; 2005. p. 354. Russian. 56. Alekseeva DN., Bakuleva NN. Klinicheskie aspekty shizofrenii, komorbidnoy s narkomaniey. Molodoy uchenyy. 2017;15:145–6. Russian. 57. Farmakoterapiya v nevrologii i psikhiatrii [Pharmacological Management of Neurological and Psychiatric Disorders]. Ed. by Enn SJ, Coyle JT. Moscow; 2007. 800 p. Russian. 58. Вгеier A, et аl. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc natl Acad Sci. 1997;94:2569–74. DOI: 10.1073/pnas.94.6.2569 59. Knаblе MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 1997;11:123–31. DOI: 10.1177/026988119701100205 60. Anokhin KV. Nobelevskaya premiya po fiziologii i meditsine za 2000 god. Priroda. 2001;(1) [Electronic resource]. URL: http://www.braintools.ru/article/8700.1177/026988119701100205.

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM